

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:19:59 ON 20 AUG 2009

=> fil .bec

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILES 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS,
ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 15:20:19 ON 20 AUG 2009
ALL COPYRIGHTS AND RESTRICTIONS APPLY. SEE HELP USAGETERMS FOR DETAILS.

11 FILES IN THE FILE LIST

=> s lactoferrin or tnf#(3a)inhibit?

FILE 'MEDLINE'

5447 LACTOFERRIN

76808 TNF#

1525646 INHIBIT?

7157 TNF#(3A)INHIBIT?

L1 12588 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'SCISEARCH'

5866 LACTOFERRIN

90280 TNF#

1329093 INHIBIT?

7734 TNF#(3A)INHIBIT?

L2 13587 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'LIFESCI'

1645 LACTOFERRIN

33188 TNF#

465299 INHIBIT?

3163 TNF#(3A)INHIBIT?

L3 4803 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'BIOTECHDS'

358 LACTOFERRIN

4081 TNF#

73760 INHIBIT?

365 TNF#(3A)INHIBIT?

L4 721 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'BIOSIS'

6409 LACTOFERRIN

99547 TNF#

1730970 INHIBIT?

7772 TNF#(3A)INHIBIT?

L5 14165 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'EMBASE'

5109 LACTOFERRIN

74462 TNF#

1409691 INHIBIT?

7536 TNF#(3A)INHIBIT?

L6 12628 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'HCAPLUS'

5834 LACTOFERRIN

87891 TNF#

2171072 INHIBIT?
10099 TNF#(3A)INHIBIT?
L7 15907 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'NTIS'

15 LACTOFERRIN
351 TNF#
23149 INHIBIT?
25 TNF#(3A)INHIBIT?
L8 40 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'ESBIOBASE'

1997 LACTOFERRIN
47596 TNF#
622524 INHIBIT?
4982 TNF#(3A)INHIBIT?
L9 6972 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'BIOTECHNO'

1498 LACTOFERRIN
22725 TNF#
301415 INHIBIT?
2552 TNF#(3A)INHIBIT?
L10 4040 LACTOFERRIN OR TNF#(3A)INHIBIT?

FILE 'WPIDS'

1194 LACTOFERRIN
8910 TNF#
324092 INHIBIT?
1884 TNF#(3A)INHIBIT?
L11 3065 LACTOFERRIN OR TNF#(3A)INHIBIT?

TOTAL FOR ALL FILES

L12 88516 LACTOFERRIN OR TNF#(3A) INHIBIT?

=> s wound (4a)(healing or repair?)

FILE 'MEDLINE'

129431 WOUND
109538 HEALING
164986 REPAIR?
L13 66440 WOUND (4A) (HEALING OR REPAIR?)

FILE 'SCISEARCH'

60451 WOUND
59361 HEALING
172224 REPAIR?
L14 23684 WOUND (4A) (HEALING OR REPAIR?)

FILE 'LIFESCI'

8635 WOUND
8986 HEALING
38552 REPAIR?
L15 3532 WOUND (4A) (HEALING OR REPAIR?)

FILE 'BIOTECHDS'

3643 WOUND
2756 HEALING
3908 REPAIR?
L16 2304 WOUND (4A) (HEALING OR REPAIR?)

FILE 'BIOSIS'

59694 WOUND

59426 HEALING
126279 REPAIR?
L17 26355 WOUND (4A) (HEALING OR REPAIR?)

FILE 'EMBASE'
96892 WOUND
84630 HEALING
146792 REPAIR?
L18 41542 WOUND (4A) (HEALING OR REPAIR?)

FILE 'HCAPLUS'
72929 WOUND
46557 HEALING
125472 REPAIR?
L19 29863 WOUND (4A) (HEALING OR REPAIR?)

FILE 'NTIS'
3278 WOUND
1331 HEALING
16838 REPAIR?
L20 339 WOUND (4A) (HEALING OR REPAIR?)

FILE 'ESBIOBASE'
13910 WOUND
12441 HEALING
47293 REPAIR?
L21 7369 WOUND (4A) (HEALING OR REPAIR?)

FILE 'BIOTECHNO'
5770 WOUND
5377 HEALING
22856 REPAIR?
L22 3603 WOUND (4A) (HEALING OR REPAIR?)

FILE 'WPIDS'
179010 WOUND
22819 HEALING
102323 REPAIR?
L23 10806 WOUND (4A) (HEALING OR REPAIR?)

TOTAL FOR ALL FILES
L24 215837 WOUND (4A) (HEALING OR REPAIR?)

=> s l12 and l24
FILE 'MEDLINE'
L25 52 L1 AND L13

FILE 'SCISEARCH'
L26 51 L2 AND L14

FILE 'LIFESCI'
L27 11 L3 AND L15

FILE 'BIOTECHDS'
L28 11 L4 AND L16

FILE 'BIOSIS'
L29 47 L5 AND L17

FILE 'EMBASE'
L30 74 L6 AND L18

```

FILE 'HCAPLUS'
L31      101 L7 AND L19

FILE 'NTIS'
L32      0 L8 AND L20

FILE 'ESBIOBASE'
L33      28 L9 AND L21

FILE 'BIOTECHNO'
L34      15 L10 AND L22

FILE 'WPIDS'
L35      117 L11 AND L23

TOTAL FOR ALL FILES
L36      507 L12 AND L24

=> s l36 not 2003-2009/py
FILE 'MEDLINE'
      4373034 2003-2009/PY
L37      22 L25 NOT 2003-2009/PY

FILE 'SCISEARCH'
      8215067 2003-2009/PY
      (20030000-20099999/PY)
L38      18 L26 NOT 2003-2009/PY

FILE 'LIFESCI'
      1254481 2003-2009/PY
L39      1 L27 NOT 2003-2009/PY

FILE 'BIOTECHDS'
      155364 2003-2009/PY
L40      1 L28 NOT 2003-2009/PY

FILE 'BIOSIS'
      3927276 2003-2009/PY
L41      21 L29 NOT 2003-2009/PY

FILE 'EMBASE'
      3746632 2003-2009/PY
L42      24 L30 NOT 2003-2009/PY

FILE 'HCAPLUS'
      8676832 2003-2009/PY
L43      34 L31 NOT 2003-2009/PY

FILE 'NTIS'
      114883 2003-2009/PY
L44      0 L32 NOT 2003-2009/PY

FILE 'ESBIOBASE'
      2226801 2003-2009/PY
L45      8 L33 NOT 2003-2009/PY

FILE 'BIOTECHNO'
      122467 2003-2009/PY
L46      12 L34 NOT 2003-2009/PY

FILE 'WPIDS'
      7340796 2003-2009/PY

```

L47 31 L35 NOT 2003-2009/PY

TOTAL FOR ALL FILES

L48 172 L36 NOT 2003-2009/PY

=> dup rem l48

PROCESSING COMPLETED FOR L48

L49 94 DUP REM L48 (78 DUPLICATES REMOVED)

=> d tot

L49 ANSWER 1 OF 94 BIOTECHDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Methods for treating or preventing inflammation (e.g. psoriasis) or
autoimmune diseases (e.g. lupus erythematosus or Crohn's disease)
comprise administering an antibody against tumor necrosis
factor-gamma-beta protein;
vector-mediated tumor necrosis factor-gamma-beta gene transfer,
expression in CHO cell and monoclonal antibody for cancer gene therapy
AU YU G; NI J; ROSEN C A; ZHANG J
AN 2002-09879 BIOTECHDS
PI WO 2002004643 17 Jan 2002

L49 ANSWER 2 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Antibacterial, antioxidant, immunomodulating and anticarcinogenic
preparation and a method for using it
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
IN Yakubovskaya, Raisa Ivanovna; Boyko, Anna Vladimirovna; Nemtsova, Elena
Romanovna; Osipova, Nadezhda Anatolievna; Sergeeva, Tatyana Vladimirovna;
Chissoy, Valery Ivanovich
AN 2002:51194 HCAPLUS
DN 136:107464

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002003910	A2	20020117	WO 2001-RU276	20010709
WO 2002003910	A3	20020620		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
RU 2165769	C1	20010427	RU 2000-118424	20000713
AU 2001077824	A	20020121	AU 2001-77824	20010709

L49 ANSWER 3 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI New hydroxamide derivatives matrix metalloproteinase and TNF
-alpha converting enzyme inhibitors for treating rheumatoid
arthritis, graft rejection, cachexia, anorexia
PI US 20020188120 A1 20021212 (200405)* EN 76[0]
IN BAKER J L; VENKATESAN A M

L49 ANSWER 4 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Composition useful for e.g. the treatment of skin inflammation e.g.
allergic contact dermatitis, comprises a fraction obtained by
chromatographic separation of a fat, oil or wax
PI US 20020182260 A1 20021205 (200331)* EN 67[25]
IN CHAVDARIAN C G; FRANCOEUR M L; LEE C; LEE J; MAK V H W; PARKS T P

L49 ANSWER 5 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI New N-hydroxy-3-substituted alkyl, aryl or heteroaryl amides, useful for treating e.g. arthritis, tumors, ulceration, diabetes and HIV infection, are matrix metalloproteinase inhibitors
 PI US 20020032186 A1 20020314 (200255)* EN 75[0]
 US 6441023 B1 20020827 (200264) EN
 IN BAKER J L; LEVIN J I; VENKATESAN A M

L49 ANSWER 6 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New non-peptide inhibitors of matrix metalloproteinase useful for the treatment of arthritis
 PI US 20020006922 A1 20020117 (200223)* EN 75[0]
 US 6462073 B2 20021008 (200274) EN
 IN BAKER J L; DAVIS J M; GROSU G T; LEVIN J I; VENKATESAN A M

L49 ANSWER 7 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl or (hetero)aryl amides are matrix metalloproteinase inhibitors, useful for the treatment of e.g. inflammation, atherosclerosis and arthritis
 PI US 6444704 B1 20020903 (200279)* EN 59[0]
 IN BAKER J L; VENKATESAN A M

L49 ANSWER 8 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New non-peptide inhibitors of matrix metalloproteinase and tumor necrosis factor-alpha converting enzyme useful for the treatment of e.g. arthritis
 PI US 6342508 B1 20020129 (200230)* EN 59[0]
 IN COLE D C; DAVIS J M; GROSU G T; VENKATESAN A M

L49 ANSWER 9 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New (hetero)aryl-substituted aliphatic carboxylic acid derivatives, useful as integrin receptor ligands for treating, e.g. atherosclerosis, restenosis, rheumatoid arthritis, cancer, osteoporosis or hypertension
 PI DE 10064823 A1 20020627 (200263)* DE 62[0]
 WO 2002051810 A2 20020704 (200263) DE
 AU 2002240846 A1 20020708 (200427) EN
 IN GENESTE H; GRAEF C I; HORNBERGER W; KLING A; KLUGE M; LANGE U; LAUTERBACH A; SEITZ W; SPRIESTERBACH R; SUBKOWSKI T

L49 ANSWER 10 OF 94 BIOTECHNO COPYRIGHT 2009 Elsevier Science B.V. on STN
 TI Tumor necrosis factor- α -induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase
 SO Journal of Biological Chemistry, (26 JUL 2002), 277/30 (27319-27327), 41 reference(s)
 CODEN: JBCHA3 ISSN: 0021-9258
 AU Han Y.-P.; Nien Y.-D.; Garner W.L.
 AN 2002:34951751 BIOTECHNO

L49 ANSWER 11 OF 94 MEDLINE on STN DUPLICATE 2
 TI Role of alpha(v)beta(3)-integrin in TNF-alpha-induced endothelial cell migration.
 SO American journal of physiology. Cell physiology, (2002 Oct) Vol. 283, No. 4, pp. C1196-205.
 Journal code: 100901225. ISSN: 0363-6143.
 AU Gao Baochong; Saba Thomas M; Tsan Min-Fu
 AN 2002465951 MEDLINE

L49 ANSWER 12 OF 94 MEDLINE on STN DUPLICATE 3
 TI Differential expression of inflammatory mediators in radiation-impaired wound healing.
 SO The Journal of surgical research, (2002 Sep) Vol. 107, No. 1, pp. 93-100.

Journal code: 0376340. ISSN: 0022-4804.

AU Schaffer Michael; Weimer Wiebke; Wider Susanne; Stulten Christina;
Bongartz Martina; Budach Wilfried; Becker Horst-Dieter
AN 2002626618 MEDLINE

L49 ANSWER 13 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Fluticasone Propionate Downregulates Nasal Fibroblast Functions Involved
in Airway Inflammation and Remodeling
SO International Archives of Allergy and Immunology (2002), 128(1), 51-58
CODEN: IAAIEG; ISSN: 1018-2438
AU Silvestri, M.; Sabatini, F.; Scarso, L.; Cordone, A.; Dasic, G.; Rossi, G.
A.
AN 2002:403439 HCAPLUS
DN 137:309359

L49 ANSWER 14 OF 94 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
STN
TI Analysis of Rabbit Tear Proteins by High Pressure Liquid
Chromatography-Electrospray Ionization-Mass Spectrometry (LC-ESI-MS).
SO ARVO Annual Meeting Abstract Search and Program Planner, (2002) Vol. 2002,
pp. Abstract No. 3140. cd-rom.
Meeting Info.: Annual Meeting of the Association For Research in Vision
and Ophthalmology. Fort Lauderdale, Florida, USA. May 05-10, 2002.
AU Zhou, L. [Reprint Author]; Beuerman, R. W.; Barathi, A. [Reprint Author];
Tan, D.
AN 2003:155162 BIOSIS

L49 ANSWER 15 OF 94 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
STN
TI NOVEL MECHANISM OF MICROGLIA ACTIVATION BY MATRIX METALLOPROTEINASE- 3
(MMP-3).
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
Vol. 2002, pp. Abstract No. 101.9. <http://sfn.scholarone.com>. cd-rom.
Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.
Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
AU Kim, Y. [Reprint Author]; Kim, S. [Reprint Author]; Park, K. [Reprint
Author]; Joh, T. [Reprint Author]
AN 2003:269293 BIOSIS

L49 ANSWER 16 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
TI Role of $\alpha(v)\beta(3)$ -integrin in TNF- α -induced endothelial
cell migration.
SO American Journal of Physiology - Cell Physiology, (Oct 2002) Vol. 283, No.
4 52-4, pp. C1196-C1205.
Refs: 44
ISSN: 0363-6143 CODEN: AJPCDD
AU Gao, Baochong (correspondence); Saba, Thomas M.; Tsan, Min-Fu
AN 2002339030 EMBASE

L49 ANSWER 17 OF 94 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on
STN
AN 2002218678 ESBIODBASE
TI Role of $\alpha v \beta 3$ -integrin in TNF- α -induced endothelial
cell migration
AU Gao, Baochong; Saba, Thomas M.; Tsan, Min-Fu
CS Gao, Baochong; Saba, Thomas M. (Department of Physiology, Albany Medical
College, Albany, NY 12208 (US)); Gao, Baochong; Saba, Thomas M. (Center
for Cell Biology and Cancer Research, Albany Medical College, Albany, NY
12208 (US)); Gao, Baochong; Tsan, Min-Fu (Laboratory of Cell Physiology,
Veterans Affairs Medical Center, Washington, DC 20422 (US))
SO American Journal of Physiology - Cell Physiology (Oct 2002) Volume 283,

Number 4 52-4, 44 refs.
 CODEN: AJPCDD ISSN: 0363-6143
 CY United States of America
 DT Journal; Article
 LA English
 SL English
 ED Entered STN: 1 Feb 2009
 Last updated on STN: 1 Feb 2009

- L49 ANSWER 18 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Preparation of peptidyl compounds as inhibitors of matrix metalloproteinases and TNF
 SO U.S., 28 pp., Cont. of U.S. 5,994,312.
 CODEN: USXXAM
 IN Montana, John; Baxter, Andrew Douglas; Owen, David Alan; Watson, Robert John; Phillipson, Neil
 AN 2001:75296 HCAPLUS
 DN 134:131815
- | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| US 6180611 | B1 | 20010130 | US 1999-315279 | 19990520 |
| ZA 9508396 | A | 19961007 | ZA 1995-8396 | 19951005 |
| US 5853623 | A | 19981229 | US 1996-644383 | 19960510 |
| US 5994312 | A | 19991130 | US 1998-124877 | 19980730 |
- L49 ANSWER 19 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New non-peptide inhibitors of matrix metalloproteinase, are useful for the treatment of arthritis
 PI US 6331563 B1 20011218 (200218)* EN 67[0]
 IN BAKER J L; GROSU G T; VENKATESAN A M
- L49 ANSWER 20 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New hydroxamic acid derivatives, useful for treating disease conditions mediated by TNF-alpha converting enzyme e.g. rheumatoid arthritis
 PI US 6277885 B1 20010821 (200165)* EN 27[0]
 IN CHEN J M; LEVIN J I
- L49 ANSWER 21 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI Ortho-sulfonamido heteroaryl hydroxamic acid matrix metalloproteinase and tumor necrosis factor alpha-converting enzyme inhibitors, used to treat e.g. atherosclerosis, tumors, arthritis and wounds
 PI US 6197795 B1 20010306 (200126)* EN 17[0]
 IN LEVIN J I; NELSON F C
- L49 ANSWER 22 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI Inhibiting pathological changes mediated by matrix metalloproteinases or TNF-alpha used for treating e.g. tumors, arthritis and infections using new and known N-hydroxyamide derivatives
 PI US 6172057 B1 20010109 (200117)* EN 58[0]
 IN BAKER J L; COLE D C; DAVIS J M; GROSU G T; HU B; JACOBSON M P; O'DELL M R; VENKATESAN A M
- L49 ANSWER 23 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN
 DUPLICATE 4
 TI Comment on: Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: A prospective randomized study [1] (multiple letters).
 SO International Journal of Radiation Oncology Biology Physics, (1 Aug 2001) Vol. 50, No. 5, pp. 1373-1374.
 ISSN: 0360-3016 CODEN: IOBPD3
 AU Makkonen, Tuula; Tuominen, Juhani; Joensuu, Heikki; Kilic, D., Dr. (correspondence)

AN 2001279185 EMBASE

L49 ANSWER 24 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

TI Delayed healing of gastric ulcers in adjuvant arthritis rats: Role of acid secretion and basic fibroblast growth factor.

SO Digestion, (2001) Vol. 63, No. 3, pp. 171-179.

Refs: 24

ISSN: 0012-2823 CODEN: DIGEBW

AU Kato, Shinichi, Dr. (correspondence); Ogawa, Yoshihiro; Tanaka, Akiko; Kunikata, Tomonori; Takeuchi, Koji; Kato, Shinichi, Dr. (correspondence); Kato, Shinichi, Dr. (correspondence)

AN 2001174967 EMBASE

L49 ANSWER 25 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI Use of new and known fused bicyclic alkanolic acid derivatives for treatment of conditions associated with e.g. matrix metalloproteinases, e.g. inflammatory or dermatological disorders

PI WO 2000069827 A1 20001123 (200104)* EN 23[0]

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ
EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI
SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AU 2000049330 A 20001205 (200113) EN

IN BATTY D; BAXTER A D; HANNAH D; OWEN D A; WATSON R J

L49 ANSWER 26 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI Compositions comprising a biologically active agent encapsulated by a carboxylic acid, useful for the oral delivery of pharmaceutical agents

PI WO 2000022909 A2 20000427 (200030)* EN 31[2]

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SL SZ TZ UG ZW

W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AU 2000010712 A 20000508 (200037) EN

IN RUSSELL-JONES G J

L49 ANSWER 27 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI New ortho-sulfonamido heteroaryl hydroxamic acids are matrix metalloproteinase and TACE inhibitors, useful for treating e.g. atherosclerosis, angiogenesis, arthritis, tumor metastasis

PI US 6162814 A 20001219 (200110)* EN 16[0]

IN LEVIN J I; NELSON F C

L49 ANSWER 28 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN

TI TNF- α regulates transforming growth factor- α expression in regenerating murine liver and isolated hepatocytes

SO Journal of Immunology (2000), 164(2), 872-878

CODEN: JOIMA3; ISSN: 0022-1767

AU Gallucci, Randle M.; Simeonova, Petia P.; Toriumi, Wataru; Luster, Michael I.

AN 2000:52466 HCAPLUS

DN 132:206764

L49 ANSWER 29 OF 94 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN

TI Absence of IL-1 or TNF receptor signalling inhibits wound healing.

SO JOURNAL OF DENTAL RESEARCH, (FEB 2000) Vol. 79, Sp. iss. SI, pp. 626-626.
MA 3859.
ISSN: 0022-0345.

AU Nooh N (Reprint); Graves D T
AN 2000:174859 SCISEARCH

L49 ANSWER 30 OF 94 MEDLINE on STN
TI The inflammatory response following treatment of abdominal aortic
aneurysms: a comparison between open surgery and endovascular repair.

SO European journal of vascular and endovascular surgery : the official
journal of the European Society for Vascular Surgery, (2000 May) Vol. 19,
No. 5, pp. 536-44.
Journal code: 9512728. ISSN: 1078-5884.

AU Odegard A; Lundbom J; Myhre H O; Hatlinghus S; Bergh K; Waage A; Bjerve K
S; Mollnes T E; Aadahl P; Lie T A; Videm V
AN 2000295332 MEDLINE

L49 ANSWER 31 OF 94 MEDLINE on STN DUPLICATE 5
TI Lactoferrin protects against UV-B irradiation-induced corneal
epithelial damage in rats.

SO Cornea, (2000 Mar) Vol. 19, No. 2, pp. 207-11.
Journal code: 8216186. ISSN: 0277-3740.

AU Fujihara T; Nagano T; Endo K; Nakamura M; Nakata K
AN 2000208243 MEDLINE

L49 ANSWER 32 OF 94 MEDLINE on STN
TI Pentoxifylline accelerates gastric ulcer healing in rats: roles of tumor
necrosis factor alpha and neutrophils during the early phase of ulcer
healing.

SO Digestion, (2000) Vol. 61, No. 3, pp. 157-64.
Journal code: 0150472. ISSN: 0012-2823.

AU Shimizu N; Watanabe T; Arakawa T; Fujiwara Y; Higuchi K; Kuroki T
AN 2000237594 MEDLINE

L49 ANSWER 33 OF 94 MEDLINE on STN DUPLICATE 6
TI Dry eye and closed eye tears.

SO Cornea, (2000 May) Vol. 19, No. 3 Suppl, pp. S44-8.
Journal code: 8216186. ISSN: 0277-3740.

AU Fukuda M; Wang H F
AN 2000290318 MEDLINE

L49 ANSWER 34 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
TI Dry eye and closed eye tears.

SO Cornea, (May 2000) Vol. 19, No. 3 SUPPL. 1, pp. S44-S48.
Refs: 20
ISSN: 0277-3740 CODEN: CORNDB

AU Fukuda, Masahiko, Dr. (correspondence); Wang, Hsiao-Fu
AN 2000189311 EMBASE

L49 ANSWER 35 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 7
TI Preparation of peptidyl compounds having MMP and TNF
inhibitory activity

SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2

IN Baxter, Andrew Douglas; Montana, John Gary
AN 1999:126878 HCAPLUS
DN 130:168663

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9907679	A1	19990218	WO 1998-GB272	19980129

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, US, UZ, VN, YU, ZW
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 US 5955435 A 19990921 US 1997-908990 19970808
 AU 9858719 A 19990301 AU 1998-58719 19980129

L49 ANSWER 36 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Screening methods and therapeutic formulations for cytokine inhibitors
 SO U.S., 50 pp., Cont.-in-part of U.S. 400,234, abandoned.
 CODEN: USXXAM

IN Mak, Vivian
 AN 1999:636053 HCAPLUS
 DN 131:276963

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962477	A	19991005	US 1998-97441	19980615
WO 9527510	A1	19951019	WO 1995-US4677	19950411
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 937460	A2	19990825	EP 1999-201333	19950411
EP 937460	A3	20000405		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 6190691	B1	20010220	US 1998-97440	19980615

L49 ANSWER 37 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New tetrahydro-1,4-benzodiazepine-3-hydroxamic acid matrix
 metalloproteinase inhibitors, used e.g. for treating rheumatoid arthritis
 or tumor metastasis and growth

PI WO 9937625 A1 19990729 (199938)* EN 149[0]
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD
 GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV
 MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
 UA UG UZ VN YU ZW
 AU 9922402 A 19990809 (200001) EN
 US 6071903 A 20000606 (200034)# EN
 BR 9907746 A 20001017 (200056) PT
 EP 1051407 A1 20001115 (200059) EN
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV NL PT RO SE
 SI
 NO 2000003828 A 20000926 (200061) NO
 ZA 9900569 A 20001025 (200061) EN 150
 CZ 2000002757 A3 20010117 (200107) CS
 CN 1293663 A 20010502 (200143) ZH
 KR 2001034406 A 20010425 (200164) KO
 JP 2002501056 W 20020115 (200207) JA 190
 HU 2001000277 A2 20020228 (200223) HU
 IN ALBRIGHT J D; DELOS S E G; DELOS SANTOS E G; DU X; SANTOS E G D

L49 ANSWER 38 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New heterocyclic matrix metalloproteinase inhibitors and tumor necrosis
 factor inhibitors

PI WO 9924408 A1 19990520 (199929)* EN 27[0]
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD
 GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD
 MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA
 UG UZ VN YU ZW
 AU 9910468 A 19990531 (199941) EN
 ZA 9810361 A 20000126 (200011) EN 25
 US 6063786 A 20000516 (200031) EN
 EP 1030845 A1 20000830 (200042) EN
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
 AU 732731 B 20010426 (200128) EN
 JP 2001522837 W 20011120 (200204) JA 33
 EP 1030845 B1 20020410 (200227) EN
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
 DE 69804843 E 20020516 (200240) DE
 ES 2173634 T3 20021016 (200279) ES
 IN BAXTER A D; BAXTER A D D D L; MONTANA J G; MONTANA J G D D L; OWEN D A;
 OWEN D A D D L

L49 ANSWER 39 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New matrix metallo:proteinase inhibiting amido-amine derivatives - also
 inhibit release of TNF-alpha from cells and are useful
 for the treatment of tumoural and inflammatory diseases
 PI WO 9902510 A1 19990121 (199910)* EN 81[0]
 RW: AT BE CH CY DE DK EA ES FI FR GB GR IE IT LU MC NL PT SE
 W: AL AU BR CA CN CZ HU ID IL JP KR MX NO NZ PL RO UA US
 AU 9888583 A 19990208 (199924) EN
 EP 925289 A1 19990630 (199930) EN
 R: DE ES FR GB IT SE
 JP 2001500533 W 20010116 (200107) JA 123
 US 6482827 B1 20021119 (200280) EN
 IN ABRATE F; ALPEGIANI M; BISSOLINO P; CORIGLI R; JABES D; PERRONE E

L49 ANSWER 40 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI Ortho-sulfonamide derivatives substituted with hydroxamic acid are matrix
 metalloproteinases and TNF-alpha converting enzyme
 inhibitors, useful for treatment of e.g. artherosclerotic,
 inflammatory, neurological and cancerous conditions
 PI US 5962481 A 19991005 (199948)* EN 15[0]
 US 6162821 A 20001219 (200102) EN
 IN LEVIN J I; NELSON F C

L49 ANSWER 41 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
 TI New sulphonamido hydroxamic acid derivatives, used to treat e.g.
 atherosclerosis, skin aging, angiogenesis, and tumour metastasis
 PI US 5929097 A 19990727 (199936)* EN 68[0]
 IN DU M T; GU Y; LEVIN J I; NELSON F C; VENKATESAN A M; ZASK A

L49 ANSWER 42 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
 reserved on STN DUPLICATE 8
 TI Nuclear factor- κ B mediates TNF- α inhibitory
 effect on α 2(I) collagen (COL1A2) gene transcription in human dermal
 fibroblasts.
 SO Journal of Immunology, (1 Apr 1999) Vol. 162, No. 7, pp. 4226-4234.
 Refs: 40
 ISSN: 0022-1767 CODEN: JOIMA3
 AU Kouba, David J.; Chung, Kee-Yang; Nishiyama, Takafumi; Vindevoghel,
 Laurence; Kon, Atsushi; Klement, John F.; Uitto, Jouni; Mauviel, Alain,
 Dr. (correspondence); Kouba, David J.; Uitto, Jouni; Kouba, David J.;
 Nishiyama, Takafumi; Vindevoghel, Laurence; Kon, Atsushi; Klement, John

F.; Uitto, Jouni; Mauviel, Alain, Dr. (correspondence); Chung, Kee-Yang; Mauviel, Alain, Dr. (correspondence); Mauviel, Alain, Dr. (correspondence)
AN 1999235934 EMBASE

L49 ANSWER 43 OF 94 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on
STN DUPLICATE 9
TI Lipoxin (LX)A(4) and aspirin-triggered 15-epi-LXA(4) inhibit tumor
necrosis factor 1 alpha-initiated neutrophil responses and trafficking:
Regulators of a cytokine-chemokine axis
SO JOURNAL OF EXPERIMENTAL MEDICINE, (21 JUN 1999) Vol. 189, No. 12, pp.
1923-1929.
ISSN: 0022-1007.
AU Serhan C N (Reprint); Hachicha M; Pouliot M; Petasis N A
AN 1999:501533 SCISEARCH

L49 ANSWER 44 OF 94 MEDLINE on STN DUPLICATE 10
TI Interleukin-1 receptor antagonist attenuates tumor necrosis factor-induced
alterations in wound breaking strength.
SO The Journal of trauma, (1999 Sep) Vol. 47, No. 3, pp. 533-7.
Journal code: 0376373. ISSN: 0022-5282.
AU Maish G O 3rd; Shumate M L; Ehrlich H P; Vary T C; Cooney R N
AN 1999426624 MEDLINE

L49 ANSWER 45 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
TI Interleukin-1 receptor antagonist attenuates tumor necrosis factor-
induced alterations in wound breaking strength.
SO Journal of Trauma - Injury, Infection and Critical Care, (Sep 1999) Vol.
47, No. 3, pp. 533-537.
Refs: 35
ISSN: 1079-6061 CODEN: JOTRFA
AU Maish III, George O., Dr. (correspondence); Shumate, Margaret L.; Ehrlich,
H. Paul; Cooney, Robert N.; Vary, Thomas C.
AN 1999329486 EMBASE

L49 ANSWER 46 OF 94 MEDLINE on STN DUPLICATE 11
TI The potential role of chemokines and inflammatory cytokines in periodontal
disease progression.
SO Clinical infectious diseases : an official publication of the Infectious
Diseases Society of America, (1999 Mar) Vol. 28, No. 3, pp. 482-90. Ref:
82
Journal code: 9203213. ISSN: 1058-4838.
AU Graves D T
AN 1999208408 MEDLINE

L49 ANSWER 47 OF 94 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on
STN
TI Lipoxin A(4) and aspirin-triggered 15-epi-LXA(4) inhibit tumor necrosis
factor-alpha-initiated neutrophil responses and trafficking: novel
regulators of a cytokine-chemokine axis relevant to periodontal diseases
SO JOURNAL OF PERIODONTAL RESEARCH, (OCT 1999) Vol. 34, No. 7, pp. 370-373.
ISSN: 0022-3484.
AU Serhan C N (Reprint); Pouliot M
AN 2000:98087 SCISEARCH

L49 ANSWER 48 OF 94 MEDLINE on STN DUPLICATE 12
TI Evaluation of bovine lactoferrin as a topical therapy for
chemotherapy-induced mucositis in the golden Syrian hamster.
SO Oral oncology, (1999 Mar) Vol. 35, No. 2, pp. 197-202.
Journal code: 9709118. ISSN: 1368-8375.
AU Clarke J; Edwards B; Srpek L; Regester G
AN 1999364014 MEDLINE

L49 ANSWER 49 OF 94 MEDLINE on STN DUPLICATE 13
 TI Transient exposure to tumor necrosis factor-alpha inhibits collagen accumulation by cultured hypertrophic scar fibroblasts.
 SO The Journal of surgical research, (1999 Nov) Vol. 87, No. 1, pp. 134-41. Journal code: 0376340. ISSN: 0022-4804.
 AU Kitzis V; Engrav L H; Quinn L S
 AN 1999459021 MEDLINE

L49 ANSWER 50 OF 94 MEDLINE on STN
 TI [Components of antibacterial and fibrinolytic activity of human saliva in normal and disordered wound healing].
 Komponenten der antibakteriellen und der fibrinolytischen Aktivitat des menschlichen Gesamtspeichels bei normaler und gestorter Wundheilung.
 SO Mund-, Kiefer- und Gesichtschirurgie : MKG, (1999 Jan) Vol. 3, No. 1, pp. 38-42.
 Journal code: 9716576. ISSN: 1432-9417.
 AU Gocke R; Rafalzyk B; Seyfarth M; Sonnenburg I; Gundlach K K
 AN 1999177693 MEDLINE

L49 ANSWER 51 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 14
 TI Preparation of peptidyl compounds having MMP and TNF inhibitory activity
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 IN Baxter, Andrew Douglas; Montana, John Gary
 AN 1998:126235 HCAPLUS
 DN 128:192938
 OREF 128:38123a,38126a

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806696	A1	19980219	WO 1997-GB2149	19970808
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9738578	A	19980306	AU 1997-38578	19970808
ZA 9707100	A	19980811	ZA 1997-7100	19970808
EP 925281	A1	19990630	EP 1997-935682	19970808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				

L49 ANSWER 52 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
 SO PCT Int. Appl., 164 pp.
 CODEN: PIXXD2
 IN Levin, Jeremy Ian; Du Mila, T.; Venkatesan, Aranapakam Mudumbai; Nelson, Frances Christy; Zask, Arie; Gu, Yansong
 AN 1998:251153 HCAPLUS
 DN 128:308308
 OREF 128:61116h,61117a

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9816503	A2	19980423	WO 1997-US18280	19971008
WO 9816503	A3	19980528		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,				

VN, YU, ZW, SZ, BE, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI,
 CM, GA, GN, ML, MR, NE, SN, TD, TG
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

CA 2268894	A1	19980423	CA 1997-2268894	19971008
AU 9851458	A	19980511	AU 1998-51458	19971008
AU 731737	B2	20010405		
EP 938471	A1	19990901	EP 1997-946246	19971008
EP 938471	B1	20011212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9712525	A	19991019	BR 1997-12525	19971008
CN 1240429	A	20000105	CN 1997-180613	19971008
HU 2000000641	A2	20001028	HU 2000-641	19971008
HU 2000000641	A3	20010228		
JP 2001504809	T	20010410	JP 1998-518448	19971008
AT 210637	T	20011215	AT 1997-946246	19971008
ES 2166102	T3	20020401	ES 1997-946246	19971008
ZA 9709233	A	19990415	ZA 1997-9233	19971015
TW 410220	B	20001101	TW 1997-86114187	19971015
KR 2000049196	A	20000725	KR 1999-703294	19990415
HK 1021178	A1	20020404	HK 2000-100090	20000106

L49 ANSWER 53 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN

TI TNF- α formation inhibitors containing sulfatide
 for autoimmune disease, inflammation and allergy

SO Jpn. Kokai Tokkyo Koho, 7 pp.

CODEN: JKXXAF

IN Matsushima, Amiji; Suzuki, Yasuo; Azuma, Hidemitsu

AN 1998:112167 HCAPLUS

DN 128:235130

OREF 128:46441a,46444a

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 10045603	A	19980217	JP 1996-200681	19960730

L49 ANSWER 54 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI New 5- or 6-substituted azulene derivatives - used as metallo-protease
 inhibitors, e.g. for treating diseases caused by matrix metallo-proteases
 or tumour necrosis factor-alpha

PI EP 887339 A1 19981230 (199905)* DE 19[0]

R: AL AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT RO SE
 SI

WO 9900355 A1 19990107 (199908) DE

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
 MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
 YU ZW

AU 9887292 A 19990119 (199922) EN

IN DICKHAUT J; GRAMS F; HAAG R

L49 ANSWER 55 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI Use of azulene derivatives as metallo-protease inhibitors - e.g. di:ethyl
 2-amino-azulene-1,3-di:carboxylate, used to treat e.g. hypertension,
 psoriasis, multiple sclerosis and diabetes

PI EP 887077 A1 19981230 (199905)* DE 13[0]

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

WO 9900118 A1 19990107 (199908) DE

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL

OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN
YU ZW

AU 9887293 A 19990119 (199922) EN

IN DICKHAUT J; GRAMS F; HAAG R

L49 ANSWER 56 OF 94 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
STN

TI Estrogen, growth factors, and carcinogenesis of the reproductive tract.
SO Dickson, R. B. [Editor]; Salomon, D. S. [Editor]. (1998) pp. 311-325.
Hormones and growth factors in development and neoplasia. print.
Publisher: Wiley-Liss, Inc., 605 Third Avenue, New York, New York
10158-0012, USA; Wiley-Liss, Ltd., Chichester, England.
ISBN: 0-471-16899-8.

AU Gray, Karen [Reprint author]; Eitzman, Benjamin; Washburn, Kimberly
Raszmann; Takahashi, Tsuneo; Sakai, Yasuhiro; Merlino, Glenn; McLachlan,
John

AN 1999:164252 BIOSIS

L49 ANSWER 57 OF 94 MEDLINE on STN DUPLICATE 15

TI Identification of a human enterocyte lipoxin A4 receptor that is regulated
by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis
factor alpha-induced IL-8 release.

SO The Journal of experimental medicine, (1998 Apr 20) Vol. 187, No. 8, pp.
1285-94.

Journal code: 2985109R. ISSN: 0022-1007.

Report No.: NLM-PMC2212233.

AU Gronert K; Gewirtz A; Madara J L; Serhan C N

AN 1998215774 MEDLINE

L49 ANSWER 58 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Temporal alterations in mRNA levels for proteinases and inhibitors and
their potential regulators in the healing medial collateral ligament

SO Biochemical and Biophysical Research Communications (1998), 252(3),
757-763

CODEN: BBRCA9; ISSN: 0006-291X

AU Reno, Carol; Boykiw, Raymond; Martinez, Maria Luisa; Hart, David A.

AN 1998:799360 HCAPLUS

DN 130:181050

L49 ANSWER 59 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN DUPLICATE 16

TI Antimicrobial peptides: An emerging concept in cutaneous biology.

SO Journal of Investigative Dermatology, (1998) Vol. 111, No. 5, pp. 739-743.
Refs: 68

ISSN: 0022-202X CODEN: JIDEAE

AU Gallo, Richard L., Dr. (correspondence); Gallo, Richard L., Dr.

(correspondence); Huttner, Kenneth M.; Gallo, Richard L., Dr.

(correspondence); Gallo, Richard L., Dr. (correspondence)

AN 1998376724 EMBASE

L49 ANSWER 60 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Estrogen, growth factors, and carcinogenesis of the reproductive tract

SO Hormones and Growth Factors in Development and Neoplasia (1998), 311-325.
Editor(s): Dickson, Robert B.; Salomon, David S. Publisher: Wiley-Liss,
New York, N. Y.

CODEN: 65ZMAY

AU Gray, Karen; Eitzman, Benjamin; Washburn, Kimberly Raszmann; Takahashi,
Tsuneo; Sakai, Yasuhiro; Merlino, Glenn; McLachlan, John

AN 1998:284398 HCAPLUS

DN 129:76556
OREF 129:15677a,15680a

L49 ANSWER 61 OF 94 MEDLINE on STN DUPLICATE 17
TI Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells.
SO European journal of biochemistry / FEBS, (1998 Jul 1) Vol. 255, No. 1, pp. 139-46.
Journal code: 0107600. ISSN: 0014-2956.
AU Martinez-Esparza M; Jimenez-Cervantes C; Solano F; Lozano J A; Garcia-Borron J C
AN 1998355661 MEDLINE

L49 ANSWER 62 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Role of tumor necrosis factor-alpha in regulating fibrotic lung repair
SO Research Communications in Molecular Pathology and Pharmacology (1998), 101(1), 69-83
CODEN: RCMPE6; ISSN: 1078-0297
AU Dubaybo, Basim A.
AN 1998:635165 HCAPLUS
DN 129:342567
OREF 129:69773a,69776a

L49 ANSWER 63 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 18
TI Preparation of mercaptoamide derivatives as metalloproteinase, TNF α and L-selectin sheddase inhibitors.
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
IN Baxter, Andrew Douglas; Montana, John; Watson, Robert John; Tiffin, Peter David
AN 1997:356489 HCAPLUS
DN 126:330548
OREF 126:64243a,64246a

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9712861	A1	19970410	WO 1996-GB2439	19961004
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9671399	A	19970428	AU 1996-71399	19961004

L49 ANSWER 64 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Peptidyl derivatives with metallo-proteinase and TNF liberation inhibitory activity - are used to treat a variety of conditions including degenerative diseases and cancer
PI WO 9738007 A1 19971016 (199750)* EN 30[0]
RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG
W: AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TR TT UA UG UZ VN YU
AU 9723026 A 19971029 (199810) EN
ZA 9702895 A 19980624 (199831) EN 25
EP 891375 A1 19990120 (199908) EN
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
US 5872146 A 19990216 (199914) EN
AU 720239 B 20000525 (200034) EN
JP 2000510103 W 20000808 (200043) JA 31

IN BAXTER A D; MONTANA J G; OWEN D A

L49 ANSWER 65 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI KDR/flk-1 promoter sequence - useful for regulation of endothelial cell
specific transcription of operably linked polypeptide-encoding sequences
PI WO 9700957 A1 19970109 (199708)* EN 70[12]
RW: AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: AU CA IL JP MX NO
AU 9662884 A 19970122 (199719) EN
EP 833907 A1 19980408 (199818) EN [0]
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 5888765 A 19990330 (199920) EN
JP 11509088 W 19990817 (199943) JA 65
AU 723325 B 20000824 (200045) EN
IN HABER E; LEE M; PATTERSON W C; PATTERSON-WINSTON C

L49 ANSWER 66 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Enhancing attachment, fixation and stabilisation of bone implant - by
administering group IIIa element-containing compound, optionally bound to
protein
PI US 5686116 A 19971111 (199804)* EN 15[0]
IN BOCKMAN R; GUIDON P

L49 ANSWER 67 OF 94 MEDLINE on STN DUPLICATE 19
TI Mutual inhibition by TGF-beta and IL-4 in cultured human bronchial
epithelial cells.
SO The American journal of physiology, (1997 Sep) Vol. 273, No. 3 Pt 1, pp.
L701-8.
Journal code: 0370511. ISSN: 0002-9513.
AU Adachi Y; Mio T; Takigawa K; Striz I; Romberger D J; Robbins R A; Spurzem
J R; Heires P; Rennard S I
AN 1997462237 MEDLINE

L49 ANSWER 68 OF 94 MEDLINE on STN
TI Differences in angiogenic potential of classically vs alternatively
activated macrophages.
SO Immunobiology, (1997 Nov) Vol. 197, No. 5, pp. 478-93.
Journal code: 8002742. ISSN: 0171-2985.
AU Kodelja V; Muller C; Tenorio S; Schebesch C; Orfanos C E; Goerdts S
AN 1998075668 MEDLINE

L49 ANSWER 69 OF 94 MEDLINE on STN DUPLICATE 20
TI Lactoferrin as a suppressor of cell migration of
gastrointestinal cell lines.
SO Journal of cellular physiology, (1997 Feb) Vol. 170, No. 2, pp. 101-5.
Journal code: 0050222. ISSN: 0021-9541.
AU Nakajima M; Shinoda I; Samejima Y; Miyauchi H; Fukuwatari Y; Hayasawa H
AN 1997162151 MEDLINE

L49 ANSWER 70 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
TI Mutual inhibition by TGF- β and IL-4 in cultured human bronchial
epithelial cells.
SO American Journal of Physiology - Lung Cellular and Molecular Physiology,
(Sep 1997) Vol. 273, No. 3 17-3, pp. L701-L708.
Refs: 40
ISSN: 1040-0605 CODEN: APLPE7
AU Adachi, Yuichi (correspondence); Mio, Tadashi; Takigawa, Keiichi; Striz,
Ilja; Romberger, Debra J.; Robbins, Richard A.; Spurzem, John R.; Heires,
Peggy; Rennard, Stephen I.; Adachi, Yuichi (correspondence)
AN 1997304680 EMBASE

L49 ANSWER 71 OF 94 Elsevier Biobase COPYRIGHT 2009 Elsevier Science B.V. on
STN
AN 1997221297 ESBIODBASE
TI Mutual inhibition by TGF- β and IL-4 in cultured human bronchial
epithelial cells
AU Adachi, Yuichi; Mio, Tadashi; Takigawa, Keiichi; Striz, Ilja; Romberger,
Debra J.; Robbins, Richard A.; Spurzem, John R.; Heires, Peggy; Rennard,
Stephen I.
CS Adachi, Yuichi; Mio, Tadashi; Takigawa, Keiichi; Striz, Ilja; Romberger,
Debra J.; Robbins, Richard A.; Spurzem, John R.; Heires, Peggy; Rennard,
Stephen I. (Pulmon. and Critical Care Med. Sect., Department of Internal
Medicine, Univ. of Nebraska Medical Center, Omaha, NE 68198-5300 (US))
SO American Journal of Physiology - Lung Cellular and Molecular Physiology
(Sep 1997) Volume 273, Number 3 17-3, 40 refs.
CODEN: APLPE7 ISSN: 1040-0605
CY United States of America
DT Journal; Article
LA English
SL English
ED Entered STN: 31 Jan 2009
Last updated on STN: 31 Jan 2009

L49 ANSWER 72 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 21
TI Pharmaceutical compositions containing peptides for wound
healing
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
IN Shimamura, Seiichi; Fukuwatari, Yasuo; Takase, Mitsunori; Shinoda, Kazumi;
Yamauchi, Koji; Kuwata, Hidefumi; Yamazaki, Natsuko
AN 1996:367654 HCAPLUS
DN 125:41764
OREF 125:7933a,7936a
PATENT NO. KIND DATE APPLICATION NO. DATE

PI JP 08081387 A 19960326 JP 1994-241894 19940909

L49 ANSWER 73 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Agents for binding to advanced glycosylation end-products, and methods of
their use
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
IN Li, Yong Ming; Vlassara, Helen; Cerami, Anthony
AN 1996:746210 HCAPLUS
DN 126:14777
OREF 126:2985h,2986a
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 9631537 A1 19961010 WO 1996-US4755 19960405
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP,
KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO,
SG, SI, SK, TR, TT, UA, UZ, VN, AZ, KZ, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG
CA 2217572 A1 19961010 CA 1996-2217572 19960405
AU 9653869 A 19961023 AU 1996-53869 19960405
EP 827511 A1 19980311 EP 1996-910765 19960405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI
JP 11504316 T 19990420 JP 1996-529784 19960405

L49 ANSWER 74 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI Peptide(s) with TNF and metallo:proteinase inhibitory
activity - useful in treatment of e.g. cancer, cardiovascular disease,
auto-immune disease, Alzheimer's disease etc.

PI WO 9635711 A1 19961114 (199701)* EN 43[0]
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD
SE SZ UG
W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS
JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN
AU 9656978 A 19961129 (199712) EN
EP 824543 A1 19980225 (199812) EN
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE
JP 11505532 W 19990521 (199931) JA 53
AU 706064 B 19990610 (199934) EN
US 5981491 A 19991109 (199954) EN

IN BAXTER A D; MONTANA J; OWEN D A

L49 ANSWER 75 OF 94 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
TI Enhancing connective and support tissue repair - by admin. of gallium
PI US 5556645 A 19960917 (199643)* EN 9[0]
IN BOCKMAN R; GUIDON P

L49 ANSWER 76 OF 94 MEDLINE on STN DUPLICATE 22
TI Immunological status of patients subjected to cardiac surgery: serum
levels of interleukin 6 and tumor necrosis factor alpha and the ability of
peripheral blood mononuclear cells to proliferate and produce these
cytokines in vitro.
SO Archivum immunologiae et therapias experimentalis, (1996) Vol. 44, No. 4,
pp. 225-34.
Journal code: 0114365. ISSN: 0004-069X.
AU Wlaszczyk A; Adamik B; Durek G; Kubler A; Zimecki M
AN 1997169614 MEDLINE

L49 ANSWER 77 OF 94 MEDLINE on STN DUPLICATE 23
TI Tumor necrosis factor-alpha inhibits collagen alpha1(I) gene expression
and wound healing in a murine model of cachexia.
SO The American journal of pathology, (1996 Jul) Vol. 149, No. 1, pp.
195-204.
Journal code: 0370502. ISSN: 0002-9440.
Report No.: NLM-PMC1865213.
AU Buck M; Houghlum K; Chojkier M
AN 1996275562 MEDLINE

L49 ANSWER 78 OF 94 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on
STN
TI The effect of tumor necrosis factor-alpha on wound
healing - An experimental study
SO ANNALES CHIRURGIAE ET GYNAECOLOGIAE, (1996) Vol. 85, Suppl. [211], pp. 9-+.
ISSN: 0355-9521.
AU Rapala K (Reprint)
AN 1996:453411 SCISEARCH

L49 ANSWER 79 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
TI The effect of tumor necrosis factor- α on wound
healing. An experimental study.
SO Annales Chirurgiae et Gynaecologiae, (1996) Vol. 85, No. SUPPL. 211, pp.
1-53.
ISSN: 0355-9521 CODEN: ACGYAG
AU Rapala, K. (correspondence)
AN 1996185449 EMBASE

L49 ANSWER 80 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Wound healing promoters, skin cosmetics or hair tonics
 containing lactoferrins and epidermal growth factor
 SO Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 IN Shimamura, Seiichi; Fukuwatari, Yasuo; Shinoda, Kazumi; Hagiwara, Tomoyuki
 AN 1995:837688 HCAPLUS
 DN 123:237860
 OREF 123:42298h,42299a

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07196529	A	19950801	JP 1993-352423	19931229

L49 ANSWER 81 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Inhibition of extracellular matrix and serum protein binding to
 Staphylococcus aureus by heparin and various polysulfated agents
 SO Medical Microbiology Letters (1995), 4(8), 397-405
 CODEN: MMLEEH; ISSN: 1018-4627
 AU Pascu, Corina; Hirmo, Siiri; Ljungh, Asa; Wadstrom, Torkel
 AN 1996:156325 HCAPLUS
 DN 124:249730
 OREF 124:45921a,45924a

L49 ANSWER 82 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN DUPLICATE 24
 TI Tumour necrosis factor α , interferon γ and dexamethasone
 regulate IGF-I-maintained collagen production in cultured human
 fibroblasts.
 SO Journal of Endocrinology, (1995) Vol. 147, No. 1, pp. 167-176.
 ISSN: 0022-0795 CODEN: JOENAK
 AU Bird, J.L.E. (correspondence); Tyler, J.A.
 AN 1995293735 EMBASE

L49 ANSWER 83 OF 94 MEDLINE on STN
 TI Tumor necrosis factor: its role in HIV/AIDS.
 SO STEP perspective, (1995 Spring) Vol. 7, No. 1, pp. 13-5.
 Journal code: 9888939.
 AU Drexler A M
 AN 2001279004 MEDLINE

L49 ANSWER 84 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN DUPLICATE 25
 TI Transforming growth factors β 1, β 2, and β 3 messenger RNA
 and protein expression in mouse uterus and vagina during estrogen-induced
 growth: A comparison to other estrogen-regulated genes.
 SO Cell Growth and Differentiation, (1994) Vol. 5, No. 9, pp. 919-935.
 ISSN: 1044-9523 CODEN: CGDIE7
 AU Takahashi, T.; Eitzman, B.; Bossert, N.L.; Walmer, D.; Sparrow, K.;
 Flanders, K.C.; McLachlan, J. (correspondence); Nelson, K.G.
 AN 1994279806 EMBASE

L49 ANSWER 85 OF 94 MEDLINE on STN DUPLICATE 26
 TI Role of protein kinase C in tumor necrosis factor induction of endothelial
 cell urokinase-type plasminogen activator.
 SO Blood, (1993 May 15) Vol. 81, No. 10, pp. 2608-17.
 Journal code: 7603509. ISSN: 0006-4971.
 AU Niedbala M J; Stein-Picarella M
 AN 1993257680 MEDLINE

L49 ANSWER 86 OF 94 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
 STN
 TI The 55-kD tumor necrosis factor receptor on human keratinocytes is

regulated by tumor necrosis factor-alpha and by ultraviolet B radiation.
SO Journal of Clinical Investigation, (1993) Vol. 92, No. 1, pp. 462-470.
CODEN: JCINAO. ISSN: 0021-9738.

AU Trefzer, Uwe; Brockhaus, Manfred; Lotscher, Hansruedi; Parlow, Frauke;
Budnik, Anne; Grewe, Markus; Christoph, Helmut; Kapp, Alexander; Schoepf,
Erwin
AN 1993:410489 BIOSIS

L49 ANSWER 87 OF 94 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
STN DUPLICATE 27
TI TUMOR NECROSIS FACTOR INDUCTION OF ENDOTHELIAL CELL UROKINASE-TYPE
PLASMINOGEN ACTIVATOR MEDIATED PROTEOLYSIS OF EXTRACELLULAR MATRIX AND ITS
ANTAGONISM BY GAMMA INTERFERON.
SO Blood, (1992) Vol. 79, No. 3, pp. 678-687.
CODEN: BLOOAW. ISSN: 0006-4971.
AU NIEDBALA M J [Reprint author]; PICARELLA M S
AN 1992:185015 BIOSIS

L49 ANSWER 88 OF 94 MEDLINE on STN DUPLICATE 28
TI Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after
partial hepatectomy.
SO The American journal of physiology, (1992 Oct) Vol. 263, No. 4 Pt 1, pp.
G579-85.
Journal code: 0370511. ISSN: 0002-9513.
AU Akerman P; Cote P; Yang S Q; McClain C; Nelson S; Bagby G J; Diehl A M
AN 1993035947 MEDLINE

L49 ANSWER 89 OF 94 BIOTECHNO COPYRIGHT 2009 Elsevier Science B.V. on STN
TI Antibodies to tumor necrosis factor- α inhibit liver regeneration
after partial hepatectomy
SO American Journal of Physiology - Gastrointestinal and Liver Physiology,
(1992), 263/4 26-4 (G579-G585)
CODEN: APGPDF ISSN: 0002-9513
AU Akerman P.; Cote P.; Shi Qi Yang; McClain C.; Nelson S.; Bagby G.J.;
Diehl A.M.
AN 1992:22331948 BIOTECHNO

L49 ANSWER 90 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
TI Antibodies to tumor necrosis factor- α inhibit liver regeneration
after partial hepatectomy.
SO American Journal of Physiology - Gastrointestinal and Liver Physiology,
(1992) Vol. 263, No. 4 26-4, pp. G579-G585.
ISSN: 0002-9513 CODEN: APGPDF
AU Akerman, P.; Cote, P.; Shi Qi Yang; McClain, C.; Nelson, S.; Bagby, G.J.;
Diehl, A.M. (correspondence)
AN 1992331966 EMBASE

L49 ANSWER 91 OF 94 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on
STN DUPLICATE 29
TI TUMOR-NECROSIS-FACTOR-ALPHA INHIBITS WOUND-HEALING IN
THE RAT
SO EUROPEAN SURGICAL RESEARCH, (SEP-DEC 1991) Vol. 23, No. 5-6, pp. 261-268.
ISSN: 0014-312X.
AU RAPALA K (Reprint); LAATO M; NIINIKOSKI J; KUJARI H; SODER O; MAUVIEL A;
PUJOL J P
AN 1992:100429 SCISEARCH

L49 ANSWER 92 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights
reserved on STN
TI An adverse wound environment activates leukocytes prematurely.
SO Archives of Surgery, (1991) Vol. 126, No. 2, pp. 225-230.

ISSN: 0004-0010 CODEN: ARSUAX

AU Moelleken, B.R.W.; Mathes, S.J., Dr. (correspondence); Amerhauser, A.;
Scheuenstuhl, H.; Hunt, T.K.
AN 1991101527 EMBASE

L49 ANSWER 93 OF 94 MEDLINE on STN
TI Inhibitory effects of tumor necrosis factor alpha on fracture healing in
rats.
SO Bone, (1989) Vol. 10, No. 6, pp. 453-7.
Journal code: 8504048. ISSN: 8756-3282.
AU Hashimoto J; Yoshikawa H; Takaoka K; Shimizu N; Masuhara K; Tsuda T;
Miyamoto S; Ono K
AN 1990166949 MEDLINE

L49 ANSWER 94 OF 94 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on
STN
TI INHIBITORY EFFECT OF GAMMA INTERFERON ON CULTURED HUMAN KERATINOCYTE
THROMBOSPONDIN PRODUCTION DISTRIBUTION AND BIOLOGIC ACTIVITIES.
SO Journal of Investigative Dermatology, (1988) Vol. 91, No. 3, pp. 213-218.
CODEN: JIDEAE. ISSN: 0022-202X.
AU NICKOLOFF B J [Reprint author]; RISER B L; MITRA R S; DIXIT V M; VARANI J
AN 1988:504241 BIOSIS

=> d ab 30,31,46-48,50,59,69,72,78,80

L49 ANSWER 30 OF 94 MEDLINE on STN
AB OBJECTIVES: to compare the inflammatory response following endovascular
and conventional AAA repair. Design: prospective study. PATIENTS AND
METHODS: ten patients were selected for open surgery (OPEN) and ten for
endovascular (ENDO) AAA repair. Leukocytes, platelets, myeloperoxidase,
lactoferrin, beta-thromboglobulin, C-reactive protein (CRP),
interleukin 6 (IL-6), tumour necrosis factor alpha (TNF-alpha) and
complement activation products were measured before, during and after
surgery. RESULTS: in the OPEN group the median hospital stay was longer
(6 vs. 12 days, $p=0.001$) and more patients required transfusion ($p=0.02$).
IL-6 and CRP increased postoperatively, most in OPEN ($p<0.01$). Platelet
counts decreased after the first angiography in ENDO ($p<0.01$) and before
aortic cross-clamping in OPEN ($p<0.05$). The decrease was larger in OPEN
($p=0.02$). Leukocyte counts decreased after the first angiography in ENDO,
and thereafter increased ($p=0.001$). An equivalent increase was observed
in OPEN after declamping ($p=0.001$). Leukocyte and platelet degranulation
products increased after the first angiography in ENDO and after
declamping in OPEN. Changes in complement activation products were small.
TNF-alpha did not change significantly. CONCLUSION: endovascular AAA
repair caused significant leukocyte and platelet activation. Based on the
timing of activation this could be caused by radiographic contrast media.
Copyright 2000 Harcourt Publishers Ltd.

L49 ANSWER 31 OF 94 MEDLINE on STN DUPLICATE 5
AB PURPOSE: Lactoferrin supplementation suppresses ultraviolet
light B (UV-B)-induced oxidation of cultures of human corneal epithelial
cells. To investigate the protective effect of lactoferrin
containing eyedrops against UV-B-induced corneal damage in vivo, we
examined lactoferrin efficacy in a rat UV-B keratitis model.
METHODS: Sprague-Dawley rats were irradiated with >10 kJ/m² after
anesthetization, and then corneal epithelial defect was observed at 24 h
postirradiation. The pre- or postapplication of vehicle or
lactoferrin-containing eyedrops was performed, and then corneal
epithelial damage was scored based on fluorescein staining. RESULTS:
Posttreatment with lactoferrin did not inhibit the extent of
corneal damage and did not affect wound healing.

However, pretreatment by topical application of lactoferrin suppressed development of a corneal epithelial defect induced by UV-B irradiation in rats. CONCLUSION: These results suggest that the presence of lactoferrin in human tear fluid may inhibit UV-induced corneal epithelial damage.

- L49 ANSWER 46 OF 94 MEDLINE on STN DUPLICATE 11
AB Inflammation is regulated by the expression of mediators that cause a number of pleiotropic events culminating in the recruitment of inflammatory cells and release of biologic mediators by leukocytes. If the inflammation is transient in nature, it can protect the host by activating defense mechanisms and initiating wound repair. However, if the inflammation is inappropriate, it can lead to considerable tissue damage. My colleagues and I have investigated the role of chemokines, particularly monocyte chemoattractant protein 1, in various pathological processes and the role of the proinflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor (TNF) in experimental periodontitis. I will discuss first the studies on chemokines and then the use of IL-1 and TNF blockers in inhibiting inflammation and bone loss in the periodontium.
- L49 ANSWER 47 OF 94 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN
AB The impact of lipoxin A(4) (LXA(4)) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF alpha)-initiated neutrophil (PMN) responses in vitro and in vivo using LX analogs that are metabolically more stable. At nanomolar levels, the LXA(4) and ATL analog 15 R/S-methyl-LXA(4) each blocked TNF alpha-stimulated IL-1 beta release by isolated human PMN in vitro. These LXA(4)-ATL actions were time- and concentration-dependent. The TNF alpha-induced IL-1 beta gene expression was also regulated by 15 R/S-methyl-LXA(4). In addition, 15 R/S-methyl-LXA(4) added to murine air pouches dramatically inhibited TNF alpha-stimulated leukocyte trafficking in vivo, as well as altered the appearance of both macrophage inflammatory peptide-2 and IL-1 beta and concomitantly stimulated IL-4 in pouch exudates. These findings from in vitro and in vivo experiments indicate that both LXA(4) and ATL are regulators of TNF alpha-directed neutrophil actions and stimulate IL-4 in exudates and thus regulate mediators that are held to play an important role in the pathogenesis of periodontal disease.
- L49 ANSWER 48 OF 94 MEDLINE on STN DUPLICATE 12
AB Bovine lactoferrin was applied topically to the oral mucosa of Syrian hamsters and assessed for its ability to decrease the severity of chemotherapy-induced oral mucositis. Results indicated that the chemotherapy agent 5-fluorouracil (5-FU) administered to hamsters on days 0 and 2 produced severe leukopenia between days 4 and 7 of the trial, and that severity of oral mucositis coincided with the suppressed immune state in these animals. Bovine lactoferrin applied continuously to oral wounds in hamsters induced by a combination of chemotherapy treatment and mild abrasion of the cheek pouch, failed to decrease the severity of mouth ulcers relative to a group receiving BSA as a control protein source. Hamster cheek pouches treated twice daily with lactoferrin had a significantly worse condition score between days 6 and 8, and days 12 and 13 ($p < 0.05$ to $p < 0.001$), a higher ulcer score between days 6 and 15 ($p < 0.05$ to $p < 0.001$) and larger ulcer area between days 7 and 14 ($p < 0.05$ to $p < 0.001$) compared to animals administered the control protein. Body weight changes between treatment and control groups showed no significant difference over the trial period. In contrast to the pre-study hypothesis, we report a detrimental effect from topical administration of bovine lactoferrin to the wounded oral mucosa of immunocompromised hamsters.

L49 ANSWER 50 OF 94 MEDLINE on STN

AB Following oral surgery, there are sometimes disturbances in wound healing. It was the aim of this investigation to look for relationships between the composition of saliva and disturbed wound healing. Resting as well as stimulated fasting whole saliva was collected from 96 patients (19 to 53 years of age) prior to oral surgery. Flow rate, pH, standard bicarbonate, total buffer bases, peroxidase, lysozyme, thiocyanate, secretory immunoglobulin A, lactoferrin, total protein, tissue type plasminogen activator, and plasminogen activator inhibitor were determined. The salivary data of eight patients who suffered from disturbed wound healing were compared to the data of 20 randomly selected patients with normal wound healing. Patients with disturbed wound healing revealed increased activities and secretion rates for peroxidase in resting saliva. In stimulated saliva, decreased secretion rates for thiocyanate and total protein were found. Not a single salivary factor was able to discriminate both groups of patients with sufficient accuracy, but with a combination of tissue type plasminogen activator, peroxidase, plus secretory immunoglobulin A measurements from resting whole saliva a clearly improved and acceptable discrimination of the two patient groups was possible. A discriminant function including six salivary factors could be used to completely separate both groups.

L49 ANSWER 59 OF 94 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN DUPLICATE 16

AB Antimicrobial peptides are part of the host defense systems of plants, insects, fish, amphibia, birds, and mammals. These small proteins were previously thought of as an evolutionarily ancient system of immune protection with little relevance to the normal function of human skin. Recent developments have found that mammalian skin expresses these gene-encoded peptide antibiotics during inflammatory events such as wound repair, contact dermatitis, and psoriasis. The presence of these peptides in the skin forms a barrier for innate host protection against microbial pathogenesis. Furthermore, antimicrobial peptides also act on animal cells by stimulating them to change behaviors such as syndecan expression, chemotaxis, and chloride secretion. The combination of effects on host cells with antimicrobial action in a single molecule represents an efficient defense and response system against injury. Understanding the action of antimicrobial peptides in skin may yield further insight into the mechanism of innate cutaneous disease control and provide new approaches to therapy of wounds and inflammatory dermatitis.

L49 ANSWER 69 OF 94 MEDLINE on STN DUPLICATE 20

AB The effects of lactoferrin (Lf), an iron-binding glycoprotein, on cell migration were investigated. Lf inhibited the cell migration of three gastrointestinal cell lines (Caco-2 cells, AGS cells, and IEC-18 cells) in vitro. Both iron-saturated (holo) and iron-depleted (apo) Lf showed this inhibitory effect. Chelation of iron in the culture medium by desferrioxamine did not affect the activity of either form of Lf. A pepsin hydrolysate of Lf exhibited effectiveness similar to that of intact Lf. These results demonstrate a novel activity of Lf and suggest a potential role for this molecule in gastrointestinal wound healing, which is independent of its iron-binding capacity.

L49 ANSWER 72 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 21

AB Pharmaceutical compns. for wound healing contain peptides (lactoferrin hydrolyzate) such as Phe-Gln-Trp-Gln-Arg-Asn or their pharmaceutically acceptable derivs. or salts as active ingredients. The peptides can be synthesized or obtained by enzymic hydrolysis of bovine lactoferrin. Tablets were

formulated containing Phe-Gln-Trp-Gln-Arg-Asn 10.0, lactose monohydrate 30.0, corn starch 19.8, crystalline cellulose 28.0, magnesium silicate pentahydrate 2.0, and magnesium stearate 0.2 mg.

L49 ANSWER 78 OF 94 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN

AB The inflammatory phase in wound healing is considered to be a preparatory process for the formation of new tissue. A monocyte-derived cytokine, tumor necrosis factor-alpha (TNF-alpha), is a highly conserved molecule known to play a major role in the pathogenesis of gram-negative shock. Besides this, previous experimental studies show that TNF-alpha may have either a beneficial or detrimental role in wound healing.

The purpose of the present study was to examine the effects of TNF-alpha on developing granulation tissue in rats as well as on rat and human granulation tissue cells in culture. Subcutaneously implanted cylindrical hollow sponges were used for studying the effects of locally applied TNF-alpha on granulation tissue in rats. These implants were treated either on the day of implantation or for the first 4 or 7 days after implantation with a solution containing various amounts of TNF-alpha while the control implants were treated correspondingly with the carrier solution only. The analyses of the granulation tissue were carried out 4, 7, 14 and 21 days after implantation. In the histological specimen these sponges were cut into small pieces and stained with Weigert van Gieson to visualize collagen. The amount of granulation tissue grown into the sponge was calculated from the cross section of every sponge.

For the cell culture studies fibroblasts were released from human and rat granulation tissue which was cut into small pieces and digested by collagenase and DNase in Hank's balanced salt solution. The cells were exposed to 1, 10, or 100 ng/ml of TNF-alpha and the rate of collagen synthesis was measured as synthesis of protein-bound H-3-hydroxyproline. The number of cells in the culture dishes was counted with Burger's hemocytometer after detaching the cells with trypsin treatment. As interleukin-1 (IL-1) and TNF-alpha overlap in many of their functions, the effects of lipopolysaccharide (LPS), human interleukin 1 beta (IL-1) and prostaglandin E(2) (PGE(2)) on experimental granulation tissue in rats as well as on rat granulation tissue cells in culture were studied with the same method.

After a single application of TNF-alpha into the sponge, no essential differences between the groups were detected. However, after daily applications of TNF-alpha for 4 days, an inhibitory effect on tissue repair was observed after 4 and 7 days. Collagen formation, indicated by the hydroxyproline content of the sponge, was significantly lower in the group treated with TNF-alpha than in the controls. This effect was not observed after 14 or 21 days. These findings were confirmed in the histological samples. In the cultures of rat granulation tissue fibroblasts TNF-alpha decreased H-3-hydroxyproline production to about 75% of that in the controls and it had also a decreasing effect on pro alpha 1(I) and pro alpha 1(III) collagen mRNA levels maximally by 67% and 77% of the control level, respectively. In the cultures of human granulation tissue fibroblasts a similar inhibiting effect on the production of collagen was seen. TNF-alpha decreased the production of H-3-hydroxyproline to 56% of the control value with a dose of 100 ng/ml. Similarly, IL-1 beta decreased hydroxyproline content of granulation tissue seven days postoperatively and PGE(2) decreased nonsignificantly the amounts of hydroxyproline but the steady-state levels of pro alpha 1(I) and pro alpha 1(III) collagen chain mRNAs were slightly elevated. In the IL-1 beta-treated fibroblast cultures collagen production decreased by 15% compared with that of the controls. PGE(2) decreased collagen production by 34% of that in the controls. This effect could be abolished with indomethacin. Indomethacin alone stimulated collagen production by 40%. In vivo IL-1 decreases the formation of normal granulation tissue.

This effect may be partly due to IL-1 stimulated secretion of PGE(2).

It is concluded that TNF-alpha inhibits the formation of new granulation tissue by decreasing the production of collagen in vivo in rat granulation tissue and in both human and rat granulation tissue fibroblast cultures. Thus, TNF-alpha may have a role in preventing hypertrophic scar formation.

L49 ANSWER 80 OF 94 HCAPLUS COPYRIGHT 2009 ACS on STN

AB Wound healing promoters, skin cosmetics or hair tonics comprise latoferrins and/or lactoferrin hydrolyzates and epidermal growth factor. As an example, an ointment contained lactoferrin 10, epidermal growth factor 0.01, white petrolatum 250, stearyl alc. 220, propylene glycol 120, sodium laurysulfate 15, Me p-hydroxybenzoate 0.25, Pr p-hydroxybenzoate 0.15 and purified water 384.59g. Cosmetics containing lactoferrins and epidermal growth factor showed skin-activating and skin metabolism-promoting activities.

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	385.30	385.52
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.64	-1.64

STN INTERNATIONAL LOGOFF AT 15:48:29 ON 20 AUG 2009